Based on the efficacy of L-asparaginase (L-ASP) as an anti- NKTCL regimen that prolonged patient survival [2], it was recommended as the first-line therapy for NK/T cell lymphoma by the National Comprehensive Cancer Network (NCCN) in 2010. This evidence concerns the gene ASPG and extranodal nasal NK/T cell lymphoma.